<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369039">
  <stage>Registered</stage>
  <submitdate>24/08/2015</submitdate>
  <approvaldate>13/10/2015</approvaldate>
  <actrnumber>ACTRN12615001067561</actrnumber>
  <trial_identification>
    <studytitle>Saline Hypertonic in Preschoolers with Cystic Fibrosis and lung structure as measured by computed tomography (CT). SHIP-CT study.</studytitle>
    <scientifictitle>A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks on lung structure in patients with Cystic Fibrosis at 3-6 years of age, in parallel with the North American SHIP clinical trial, as measured by computed tomography (CT). </scientifictitle>
    <utrn>U1111-1172-7860 </utrn>
    <trialacronym>SHIP-CT</trialacronym>
    <secondaryid>NIL to date</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Experimental: Active Treatment Group 
7% Hypertonic Saline administered via inhalation twice daily for 48 weeks.

Drug - 7% Hypertonic Saline (HS) 
Administered via inhalation of 4mL twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor.
</interventions>
    <comparator>Active Comparator: Control Group 
0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks.

Drug - 0.9% Isotonic Saline (IS) 
Administered via inhalation of 4mL twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Difference in the PRAGMA-CF score: the volume proportion of the lung with structural airways disease (%Dis), measured from chest CT images at 48 weeks between treatment arms </outcome>
      <timepoint>48 weeks after commencement of intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Composite outcome of longitudinal change in airway disease, bronchiectasis and trapped air, from baseline to end of study as established by PRAGMA-CF on CT scans</outcome>
      <timepoint>at baseline and 48 weeks after commencement of intervention. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with bronchiectasis as established by PRAGMA-CF on CT scans</outcome>
      <timepoint>48 weeks after commencement of intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Longitudinal change in LCI from baseline to 48 weeks measured by N2 MBW</outcome>
      <timepoint>48 weeks after commencement of intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Protocol defined pulmonary exacerbation rate, by SAE review where a patient has ben admitted to hospital following a pulmonary exacerbation</outcome>
      <timepoint>48 weeks after commencement of intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health-related quality of life as measured by the modified parent-reported CFQ-R for preschoolers</outcome>
      <timepoint>48 weeks after commencement of intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:
   a) A documented sweat chloride greater than or equal to 60 mEq/L by quantitative pilocarpineiontophoresis (QPIT)
   b) A documented genotype with two disease-causing mutations in the CFTR gene
2. Informed consent by parent or legal guardian
3. Age greater than or equal to 36 months and less than or equal to 72 months at screening visit
4. Ability to comply with medication use, study visits and study procedures as judged by the site investigator 
5. Ability to perform a chest CT at the enrolment visit 
</inclusivecriteria>
    <inclusiveminage>36</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>72</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Chest CT within 8 months prior to the Screening visit
2. Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset within 3 weeks preceding screening or enrolment visit
3. Acute wheezing at screening or enrolment visit 
4. Oxygen saturation &lt; 95% (&lt;90% in centres located above 4000 feet elevation) at screening or enrolment visit 
5. Other major organ dysfunction, excluding pancreatic dysfunction
6. Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator
7. Investigational drug use within 30 days prior to screening or enrolment visit 
8. Treatment with inhaled HS at any concentration within 30 days prior to screening or enrolment visit
9. Start of any additional inhaled saline solution at any concentration, or other hydrating agent such as mannitol or mucolytic drug such as dornase alpha within 30 days prior or following the Screening or Enrolment visit
10. Chronic lung disease not related to CF
11. Inability to tolerate first dose of study treatment at the enrolment visit
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A central Coordinating Centre in The USA will design and maintain a secure website system for enrolment and randomisation assignments. Only authorized site personnel are given access to the randomisation pages. On the website, authorized site personnel will enter participant eligibility information and verify that the parent/guardian signed informed consent. The system will verify that the participant is eligible and then provide the authorized site personnel with a unique randomisation assignment number that matches a number on the treatment (HS or IS) package stored at the site . Randomisation to HS or IS will be stratified by age (36 to 54 months, 55 to 72 months). </concealment>
    <sequence>The randomisation list will be created based on random permuted blocks stratified on age. Electronic copies of the randomisation lists will be archived in a secure off-site location for the duration of the trial and for three years thereafter.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>120 patients (approximately 55 subjects from Australia, 55 from Europe, and 10 from two US centres) will be recruited to the study. Multiple linear regression will be used to determine the cross-sectional (values at end of study) and longitudinal (change in outcomes between beginning and end of study) relationships between LCI, the volume proportion of the lung with structural airways disease assessed by PRAGMA-CF  and secondary PRAGMA-CF outcomes percentage bronchiectasis and trapped air), and airway dimensions relative to adjacent arteries outcomes, with exposure variables included as appropriate. The relative ability of PRAGMA-CF and LCI to discriminate between treatment and active comparator arms will be determined by using linear regression against percentage disease and LCI in separate analyses, in the subset of patients with matched LCI and CT data.

For the power calculation, we used the mean (standard deviation) %Dis as measured on TLC CTs in fifty 4-6 year old children in the Perth CF cohort: 5.18 (2.54)%, with a range of 1.05  14.13%. A sample size of 50 in equal size groups with alpha=0.05 and beta=0.80 will be able to detect a difference of 1.44% (i.e. relative difference between the two treatment arms of 28% given the anticipated level of 5.18%). We estimate that we will fail to acquire a scan, or scan of sufficient quality at the end of study in around 20% of children. Hence we aim to enrol approximately 60 patients per group to end up with 50 patients per group with a chest CT scan.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>10/04/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>30/04/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/05/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA,VIC</recruitmentstate>
    <hospital>Princess Margaret Hospital - Subiaco</hospital>
    <hospital>The Children's Hospital at Westmead - Westmead</hospital>
    <hospital>Sydney Children's Hospital - Randwick</hospital>
    <hospital>The Royal Childrens Hospital - Parkville</hospital>
    <hospital>Lady Cilento Children's Hospital - South Brisbane</hospital>
    <hospital>John Hunter Children's Hospital - New Lambton</hospital>
    <hospital>Womens and Childrens Hospital - North Adelaide</hospital>
    <postcode>6008 - Subiaco</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>2305 - New Lambton</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Telethon Kids Institute</primarysponsorname>
    <primarysponsoraddress>PO Box 855, West Perth, Western Australia, 6872 </primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cystic Fibrosis Foundation Therapeutics</fundingname>
      <fundingaddress>6931 Arlington Road, Bethesda, Maryland 20814</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Cystic Fibrosis Foundation Therapeutics</sponsorname>
      <sponsoraddress>6931 Arlington Road, Bethesda, Maryland 20814</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Erasmus Medical Centre</sponsorname>
      <sponsoraddress>Erasmus Medical Centre, P.O. Box 2060, 3000 CB Rotterdam
Netherlands

</sponsoraddress>
      <sponsorcountry>Netherlands</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Collaborative Health Studies Coordinating Center
</othercollaboratorname>
      <othercollaboratoraddress>University of Washington, Collaborative Health Studies Coordinating Center, Building 29, Suite 310, 6200 NE 74th Street, Seattle, WA 98115-8160

</othercollaboratoraddress>
      <othercollaboratorcountry>United States of America</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>University of Washington School of Medicine, Division of Pulmonary Medicine, Seattle Childrenâ€™s Hospital                 		

</othercollaboratorname>
      <othercollaboratoraddress>Seattle Childrens Hospital, P.O. Box 537, Seattle, WA 98145-5005
</othercollaboratoraddress>
      <othercollaboratorcountry>United States of America</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>People with cystic fibrosis (CF) often have thick mucus in the airways of the lungs that is hard to cough up. The mucus builds up and eventually leads to chronic cough and lung infections. Research has shown that even young children with CF may have thickened mucus in the lungs.
Inhaling a concentrated salt solution, called hypertonic saline (HS), may help thin the mucus in the lungs. Thinning the mucus can make it easier to cough up. This helps to clear the lungs and improve lung health. Research studies about the safety and effectiveness of inhaled HS have been done in adults and children with CF 6 years of age and older. Patients in these studies took HS for up to a year. HS appears to be a safe treatment in these age groups. The main side effects were cough, throat irritation, and wheezing. The use of HS in older children and adults decreased the need for antibiotics for acute respiratory infections. It also improved lung function and quality of life.  HS is now routinely used by many CF patients over 6 years of age. Because HS treats a very early step in the chain of events that leads to chronic lung problems in people with CF, it may be particularly helpful when started early in life. 
Based on several studies, HS appears to be safe in children less than 6 years of age, but its effectiveness has been difficult to measure.  In a previous study, children less than 6 year-old receiving HS had the same number of lung infections as children receiving normal saline. However, we think that children this young need a more sensitive test to see if HS works in preventing lung damage.  In this study Computed Tomography (CT) scans will be used to get an image of the lung. In addition a new type of breathing test, called Multiple Breath Washout (MBW), will be used. This is relatively easy for preschool children to perform, and may allow us to measure the effectiveness of HS in preschool children with CF. The MBW tests measures lung function. This study will be conducted in parallel with the North American SHIP001 clinical study, registered on Clinicaltrials.gov NCT02378467. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname> Princess Margaret Hospital for Children Ethics Committee </ethicname>
      <ethicaddress>Level 1, Children's Clinical Research Facility
 Princess Margaret Hospital
 Roberts Road, Subiaco WA 6008
 GPO Box D184
 Perth WA 6840</ethicaddress>
      <ethicapprovaldate>28/07/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>13/10/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Stephen Stick</name>
      <address>The Telethon Kids Institute, 
PO BOX 855, West Perth, Western Australia, 6872 

</address>
      <phone>+61 (0)8 9340 8830</phone>
      <fax />
      <email>Stephen.Stick@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Nat Eiffler</name>
      <address>The Telethon Kids Institute, 
PO BOX 855, West Perth, Western Australia, 6872 </address>
      <phone>+61 (0)8 9489 7814</phone>
      <fax />
      <email>nat.eiffler@telethonkids.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Stephen Stick</name>
      <address>The Telethon Kids Institute, 
PO BOX 855, West Perth, Western Australia, 6872 </address>
      <phone>+61 (0)8 9340 8830</phone>
      <fax />
      <email>Stephen.Stick@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Nat Eiffler</name>
      <address>The Telethon Kids Institute, 
Perth WA, PO BOX 855</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>